A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER PHASE 3 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND EFFICACY OF XEN1101 AS ADJUNCTIVE THERAPY IN FOCAL-ONSET SEIZURES

Registry ID

XPF-010-301

Source registry

HEALTH_CANADA

Status

Closed

Phase

PHASE3

Study type

INTERVENTIONAL

Sponsor

XENON PHARMACEUTICALS INC

Start date

2024-07-12

Completion date

2026-02-13

Last update

2022-12-16

Conditions

• FOCAL-ONSET SEIZURES

View on source registry